Drug Trial Radar · NCT00056056
Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides
Last checked: Nov 20, 2026Latest source record: Jul 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
93
Actual
Start
Jan 2003
Primary completion
May 2010
Study completion Jun 2011
Sponsor
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTCResearch network
- Sponsor type
- Research network
- First posted
- Mar 7, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Ultraviolet light therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. It is not yet known whether ultraviolet light therapy is more effective with or without bexarotene in treating mycosis fungoides. PURPOSE: Randomized phase III trial to compare the effectiveness of ultraviolet light therapy using methoxsalen with or without bexarotene in treating patients who have mycosis fungoides.
Conditions
- Lymphoma
Interventions
bexaroteneDrug
The recommended initial dosage of Bexarotene (75 mg Bexarotene capsules to be administered according to body surface area) for patients entered in this trial is 300 mg/m2 /once a day, taken orally, till CCR, PD, unacceptable toxicity, 16 weeks of treatment, whichever comes first
methoxypsoralenDrug
The dose of methoxypsoralen, as conventional capsules or liquid-filled capsules, is based on the patient's weight. The standard dose of 0.6 mg/kg will be given to all patients three times weekly - Increasing dose of PUVA according to a set protocol after a Minimal Phototoxic Dose (MPD) testing.
UV light therapyProcedure
Initial UVA light exposure times should be based on the minimal phototoxic dose (MPD) for the specific light source being used. MPD can be determined by irradiating several skin areas 2 cm in diameter with varying light exposure times and determining the exposure time that produces erythema at 72 hours. The initial dose of UVA administered will be 70% of the MPD. The dose of UVA for the subsequent UVA sessions will be increased according to a standard protocol consisting of 20% increments with each successive treatment session depending on the presence of erythema.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate (complete clinical response [CCR) and partial response [PR])Time frame: 35 months after first patient in
Locations
28 sites in 13 countries. Site status is shown where the registry gives one.
Karl-Franzens-University Graz
Graz, Austria
Allgemeines Krankenhaus - Universitatskliniken
Vienna, Austria
Ghent University
Ghent, Belgium
U.Z. Gasthuisberg
Leuven, Belgium
Bispebjerg Hospital
Copenhagen, Denmark
Helsinki University Central Hospital
Helsinki, Finland
Centre Hospitalier Universitaire Henri Mondor
Créteil, France
CHR Hotel Dieu
Nantes, France
Klinikum der Stadt Mannheim
Mannheim, Germany
Klinikum Minden
Minden, Germany
Hospital Universitario Insular de Gran Canaria
Tübingen, Germany
Southwest German Cancer Center at Eberhard-Karls-University
Tübingen, Germany
Medizinische Klinik und Poliklinik II - Universitaetsklinikum Wuerzburg
Würzburg, Germany
Semmelweis University
Budapest, Hungary
County Hospital
Kaposvár, Hungary
Rabin Medical Center - Beilinson Campus
Petah Tikva, Israel
Spedali Civili di Brescia
Brescia, Italy
Istituto Dermopatico Dell' Immacolata
Rome, Italy
Universita di Torino
Turin, Italy
Leiden University Medical Center
Leiden, Netherlands
Hospital de la Santa Cruz i Sant Pau
Barcelona, Spain
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital Universitari de Bellvitge
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Nuestra Senora de la Candelaria
Santa Cruz de Tenerife, Spain
UniversitaetsSpital Zuerich
Zurich, Switzerland
St. Thomas' Hospital
London, England, United Kingdom
Royal Infirmary of Edinburgh at Little France
Edinburgh, Scotland, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.